96567-93-0

Basic information

• Product Name: 1-BENZYL-3-METHYLPYRROLIDIN-3-OL
• Synonyms: 1-BENZYL-3-METHYLPYRROLIDIN-3-OL;3-Pyrrolidinol, 3-methyl-1-(phenylmethyl)-
• CAS NO: 96567-93-0
• Molecular Formula: C₁₂H₁₇NO
• Molecular Weight: 191.28
• Mol File: 96567-93-0.mol

Chemical Properties

• Boiling Point: 291.9 °C at 760 mmHg
• Flash Point: 90.2 °C
• Appearance: /
• Density: 1.102 g/cm³
• Vapor Pressure: 0.000867mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-BENZYL-3-METHYLPYRROLIDIN-3-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-3-METHYLPYRROLIDIN-3-OL(96567-93-0)
• EPA Substance Registry System: 1-BENZYL-3-METHYLPYRROLIDIN-3-OL(96567-93-0)

Safety Data

• Hazardous Substances Data: 96567-93-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-3-methylpyrrolidin-3-ol is used as a therapeutic agent for its potential anti-inflammatory properties, which may contribute to the treatment of various inflammatory conditions. Its neuroprotective capabilities also position BMPO as a candidate for the management of neurodegenerative diseases, where it could potentially slow disease progression or alleviate symptoms.
Used in Research and Development:
In the realm of scientific research, 1-Benzyl-3-methylpyrrolidin-3-ol serves as a subject of study for its potential to combat oxidative stress, a significant factor in many pathological conditions. Researchers are exploring BMPO's mechanisms of action and its interactions with biological systems to better understand and harness its potential benefits.
Used in Neuroprotection:
1-Benzyl-3-methylpyrrolidin-3-ol is utilized as a neuroprotective agent, particularly in the context of neurodegenerative diseases. Its role in this application is to potentially shield neurons from damage caused by oxidative stress and inflammation, thereby preserving neuronal function and integrity.
While the provided materials do not specify different industries for the uses of BMPO, the general applications mentioned above are based on the compound's described properties and potential therapeutic uses. Further research would be necessary to delineate specific industrial applications and to develop appropriate formulations or delivery systems for BMPO's use in various settings.

InChI:InChI=1/C12H17NO/c1-12(14)7-8-13(10-12)9-11-5-3-2-4-6-11/h2-6,14H,7-10H2,1H3

Upstream product

• 775-16-6 N-benzyl-3-pyrrolidinone 
• 75-16-1 methylmagnesium bromide 
• 5291-77-0 1-benzyl-2-pyrrolidone 

Downstream Products

• 96567-94-1 N-(1-benzyl-3-methylpyrrolidin-3-yl)acetamide 
• 1312756-35-6 3-hydroxy-3-methylpyrrolidine 
• 921592-91-8 3-methylpyrrolidin-3-ol monohydrochloride 
• 1404063-61-1 (4R)-3-(1-benzyl-3-methylpyrrolidin-3-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride 
• 1404062-75-4 3-(1-benzyl-3-methylpyrrolidin-3-yl)-5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 2135304-43-5 6-((3S,4S)-3,4-dihydroxypyrrolidin-1-yl)-2-((S)-3-hydroxy-3-methylpyrrolidin-1-yl)-4-(triifluoromethyl)nicotinonitrile 
• 147459-52-7 3-tert-butoxycarbonylamino-3-methyl-pyrrolidine 
• 181114-75-0 1-Benzyl-3-(N-t-butoxycarbonylamino)-3-methylpyrrolidine 
• 96567-95-2 N-(3-methyl-3-pyrrolidinyl)acetamide 

Relevant articles and documents

Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK)

Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders. Until now, studies on KHK inhibition with small molecules have been limited due to the lack of viable in vivo pharmacological tools. Herein we report the discovery of 12, a selective KHK inhibitor with potency and properties suitable for evaluating KHK inhibition in rat models. Key structural features interacting with KHK were discovered through fragment-based screening and subsequent optimization using structure-based drug design, and parallel medicinal chemistry led to the identification of pyridine 12.

1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof

The present invention relates to a 1,4-dihydropyridine-3,5-dicarboxylate compound of general compound (I), a process for preparing the same, a use thereof for the manufacture of a medicament for treating and/or preventing kidney injury, cardiovascular diseases and/or endocrine diseases, as well as a pharmaceutical composition and a pharmaceutical formulation containing said compounds, wherein the definitions of R1, R2, R3, R4, R5, R6, R7, R8, m, n1, n2, p and q are the same as those defined in the description.

1,4-DIHYDROPYRIDINE -3,5-DICARBOXYLATE DERIVATIVES, PREPARATION METHODS AND USES THEREOF

The present invention relates to a 1,4-dihydropyridine-3,5-dicarboxylate compound of general compound (I), a process for preparing the same, a use thereof for the manufacture of a medicament for treating and/or preventing kidney injury, cardiovascular diseases and/or endocrine diseases, as well as a pharmaceutical composition and a pharmaceutical formulation containing said compounds, wherein the definitions of R1, R2, R3, R4, R5, R6, R7, R8, m, n1, n2, p and q are the same as those defined in the description.

AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment

PYRAZOL DERIVATIVES

The invention is concerned with novel pyrazol derivatives of formula (I), wherein R1, R2, R3, R4, X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention is directed to certain {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1

This invention relates to novel compounds of the Formula I, II, III, IHa, NIb, IV, IVa, IVb, IVc, IVd, IVe, V, Va, Vb1 Vl, Vla, VIb, VII, Vila, VIIb, VIII, Vllla, VIIIb, IX, IXa, X, and Xa, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

Novel Compounds 679

The invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, wherein R1, R2, R3

1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.

On the Ritter reaction of cyclic hydroxyamines: Synthesis of conformationally-restricted reduced amide dipeptide isosteres

The Ritter reactions of 3-alkyl-3-hydroxyazetidine or -piperidine derivatives give low yields of the desired products, whereas the 3-alkyl-3-hydroxy-pyrrolidine and 4-alkyl-4-hydroxy-piperidine derivatives react smoothly to give the corresponding acetamides. An alternative route to 3-acylamino-3-alkylpiperidines, which were designed as conformationally-restricted reduced amide dipeptide isosteres, was devised from nipecotic acid vai a Hofmann rearrangement.